OMER Stock Forecast: Omeros Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$13
−5.71% on the day

The 3 Wall Street analysts covering Omeros Corp. hold a median 12-month price target of $28 — +108.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 81 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.0B
Ticker Nerd rank
81/ 100
Median analyst target
$28
Analysts covering
3
Revenue$28.5M
Operating income$74K
Net income$13.2M
Free cash flow$4.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−24.5%
1M
−20.2%
YTD
−23.1%
1Y
+60.5%
From 52W high
−37.2%
From 52W low
+60.5%
$8
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Omeros Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
81/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Quality
83
Issuance
78
Growth
78
Value
74
Revisions
59
Accruals
24
Volatility
22

Momentum (91): The shares have been drifting up relative to others.

Volatility (22): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OMER stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OMER, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26OMERHigh $33Median $28Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2
Buy
1
Hold
0
Sell
$22
Low
$28
Median
$33
High

The green dot is the last close — the median target sits +108.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Nov 2026HC Wainwright & Co.ReiteratesBuy$33
14 Oct 2026Cantor FitzgeraldReiteratesOverweight$22
22 Sept 2026Cantor FitzgeraldUpgradeOverweight$22
26 June 2026HC Wainwright & Co.MaintainsBuy$40 → $33
10 June 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026HC Wainwright & Co.ReiteratesBuy—
21 Apr 2026D. Boral CapitalMaintainsBuy—
27 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026HC Wainwright & Co.MaintainsBuy—
24 Dec 2025D. Boral CapitalMaintainsBuy—
1 Dec 2025D. Boral CapitalMaintainsBuy—
14 Nov 2025D. Boral CapitalMaintainsBuy—
16 Oct 2025D. Boral CapitalMaintainsBuy—
15 Oct 2025D. Boral CapitalMaintainsBuy—
15 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Oct 2025NeedhamReiteratesHold—
15 Oct 2025WBB SecuritiesReiteratesStrong Buy—
3 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OMER.

Market Radar

This page is one stock. Monday covers all of them.

OMER appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OMER vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Omeros Corp. returned +60.5% against +6.9% for the S&P 500, dividends included.

OMER vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26OMERS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OMER analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+81.6%
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.6×

Cheaper than 52% of US stocks

Price / sales
13.8×

Cheaper than 10% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
188.4%

Higher than 95% of US stocks

Earnings growth (YoY)
—
Gross margin
97.2%

Higher than 99% of US stocks

Operating margin
−56.4%

Higher than 17% of US stocks

Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−12.1%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Omeros Corp. has a market value of $1.0B and an enterprise value of $1.1B.

  • Revenue in the twelve months to 30 June 2026: $38.4M.

  • Net income over the same four quarters: $124.8M, a 324.9% net margin.

  • Diluted earnings per share, trailing twelve months: $1.28.

  • Free cash flow in the twelve months to 30 June 2026: −$68.7M.

  • Omeros Corp. spent $9.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 72.1M.

  • Trailing P/E: 16.6×; forward P/E: 12.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Omeros Corp. employs 175 people — $220K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

OMER and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OMEROmeros Corp.$1.0B81
ANROAlto Neuroscience, Inc.$986.1M57
CTYCity Therapeutics, Inc.$999.3M1
NKTRNektar Therapeutics$1.0B40
SPTXSeaport Therapeutics, Inc.$957.2M13
INBXInhibrx Biosciences, Inc.$1.0B37
SGPSpyGlass Pharma, Inc.$1.0B1

Take a look at OMER’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Omeros Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about OMER

What is the OMER stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Omeros Corp. have a median 12-month price target of $28, with estimates ranging from $22 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OMER stock a buy right now?

Of the 3 analysts covering Omeros Corp., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omeros Corp. 81 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OMER?

As at 21 Nov 2026, Omeros Corp. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will OMER stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +108.2% from the last close, and Ticker Nerd's factor model ranks Omeros Corp. 81 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OMER stock forecast for 2030?

No analyst covering Omeros Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $33 over the next 12 months.

How has OMER stock performed over the past year?

Omeros Corp. returned +60.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Omeros Corp. do?

Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies, and central nervous system disorders.

Company

About Omeros Corp.

Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies, and central nervous system disorders. Its portfolio includes commercial and development-stage programs designed to address unmet medical needs across hematology, nephrology, immunology, oncology, and addiction-related conditions. Omeros also works on targeted therapeutics that modulate the complement pathway, a key part of the immune system involved in several serious diseases. Headquartered in Seattle, Washington, Omeros Corp. plays a specialized role in the biotechnology market by advancing differentiated therapies from research through commercialization.

CEO Dr. Gregory A. Demopulos M.D. · 175 employees · United States · https://www.omeros.com